Research ArticleCLINICAL INVESTIGATIONS
Impact of Intravenous Insulin on 18F-FDG PET in Diabetic Cancer Patients
Félix-Nicolas Roy, Sylvain Beaulieu, Luc Boucher, Isabelle Bourdeau and Christian Cohade
Journal of Nuclear Medicine February 2009, 50 (2) 178-183; DOI: https://doi.org/10.2967/jnumed.108.056283
Félix-Nicolas Roy
Sylvain Beaulieu
Luc Boucher
Isabelle Bourdeau
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Impact of Intravenous Insulin on 18F-FDG PET in Diabetic Cancer Patients
Félix-Nicolas Roy, Sylvain Beaulieu, Luc Boucher, Isabelle Bourdeau, Christian Cohade
Journal of Nuclear Medicine Feb 2009, 50 (2) 178-183; DOI: 10.2967/jnumed.108.056283
Related Articles
Cited By...
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues
- Do Hyperglycemia and Diabetes Affect the Incidence of False-Negative 18F-FDG PET/CT Studies in Patients Evaluated for Infection or Inflammation and Cancer? A Comparative Analysis
- Reply: The Twilight Saga of Insulin Administration in Hyperglycemic Patients Undergoing 18F-FDG PET
- The Twilight Saga of Insulin Administration in Hyperglycemic Patients Undergoing 18F-FDG PET